Stock Scorer

CollPlant Biotechnologies Ltd (CLGN)

CollPlant Biotechnologies Ltd reported revenue of 179K USD for the quarter ending 30 June 2025, down 74.1% from 691K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '25 · ending 30 June 2025 179K -74.1%
Gross Profit Q2 '25 · ending 30 June 2025 -7K -102.7%
Operating Income Q2 '25 · ending 30 June 2025 -3.2M —
Net Income Q2 '25 · ending 30 June 2025 -3.3M —
Cost of Revenue Q2 '25 · ending 30 June 2025 186K -56.6%
Shares Outstanding Q2 '25 · ending 30 June 2025 11.8M +16.1%
EPS 2025 · ending 31 December 2025 -0.94 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2.4M-11.5M-11.5M-9.4M
20242024-12-31 515K-17.3M-16.6M-14.6M
20232023-12-31 11M-7.5M-7M-3.7M
20222022-12-31 299K-17.1M-16.9M-15M
20212021-12-31 15.6M65K237K1.1M
20202020-12-31 6.1M-5.6M-5.8M-4.9M
20192019-12-31 2.3M-7.6M-11.2M-7.2M
20182018-12-31 5M-4.2M-6.2M-2M
20172017-12-31 463K-6M-6.1M-5.1M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '252025-06-30179K
Q2 '242024-06-30249K
Q2 '232023-06-3010.2M
Q2 '222022-06-3066K
Q2 '212021-06-30691K
Q2 '202020-06-30823K
Q2 '192019-06-30606K
Q2 '182018-06-30182K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '252025-06-30-7K
Q2 '242024-06-30-287K
Q2 '232023-06-309.6M
Q2 '222022-06-3023K
Q2 '212021-06-30262K
Q2 '202020-06-3075K
Q2 '192019-06-30143K
Q2 '182018-06-30115K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '252025-06-30-3.2M
Q2 '242024-06-30-4.4M
Q2 '232023-06-305.7M
Q2 '222022-06-30-4.2M
Q2 '212021-06-30-3.1M
Q2 '202020-06-30-1.9M
Q2 '192019-06-30-1.8M
Q2 '182018-06-30-1.4M

Net Income Quarterly

PeriodEndingNet Income
Q2 '252025-06-30-3.3M
Q2 '242024-06-30-4.2M
Q2 '232023-06-305.8M
Q2 '222022-06-30-4.3M
Q2 '212021-06-30-3M
Q2 '202020-06-30-2M
Q2 '192019-06-30-1.2M
Q2 '182018-06-30-1.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '252025-06-30186K
Q2 '242024-06-30536K
Q2 '232023-06-30615K
Q2 '222022-06-3043K
Q2 '212021-06-30429K
Q2 '202020-06-30748K
Q2 '192019-06-30463K
Q2 '182018-06-3067K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '252025-06-3011.8M
Q2 '242024-06-3011.5M
Q2 '232023-06-3011.8M
Q2 '222022-06-3011.1M
Q2 '212021-06-3010.2M
Q2 '192019-06-304.7M
Q2 '182018-06-304.3M
Q2 '172017-06-30130.6M

EPS Annual

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
FY252025-12-31-0.94
FY242024-12-31-1.45
FY232023-12-31-0.62
FY222022-12-31-1.53
FY212021-12-310.02